|Other Names||Alkaline phosphatase, tissue-nonspecific isozyme, AP-TNAP, TNSALP, Alkaline phosphatase liver/bone/kidney isozyme, ALPL|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1474a was selected from the N-term region of human ALPL. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||This isozyme may play a role in skeletal mineralization.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The genes for the first three are located together on chromosome 2 while the tissue non-specific form is located on chromosome 1. This protein is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. The exact physiological function of the alkaline phosphatases is not known. A proposed function of this form of the enzyme is matrix mineralization, however, mice that lack a functional form of this enzyme show normal skeletal development. This enzyme has been linked directly to a disorder known as hypophosphatasia, a disorder that is characterized by hypercalcemia and includes skeletal defects. The character of this disorder can vary, however, depending on the specific mutation since this determines age of onset and severity of symptoms.
Panuccio,V., Am. J. Kidney Dis. 50 (6), 1001-1008 (2007)Brun-Heath,I., Eur J Med Genet 50 (5), 367-378 (2007)So,P.P., J. Rheumatol. 34 (6), 1313-1322 (2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.